Trade LTRN stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Lantern Pharma Inc. (LTRN) is trading at US$0.83, down 8.79% today as of Oct 8, 16:00 EDT. The company has a market capitalisation of US$29.91M. Over the past 52 weeks, LTRN has traded between US$0.83 and US$4.69. On Syfe you can trade LTRN with $0 commission and add it to your watchlist.
| Previous close | US$0.91 |
|---|---|
| Market cap | US$29.91M |
| 52-week range | US$0.83 – US$4.69 |
| Volume | 248.83K |
| Exchange | US |
Lantern Pharma Inc.
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Year: 2020
Lantern Pharma Says Zirdafulven Phase 1b/2 Trial in Bladder Cancer Cleared by European Medicines Agency
Jul 28, 12:35 PM · MT Newswires
Lantern Pharma Receives US Patent Allowance for Cancer Drug LP-184
Jul 23, 12:57 PM · MT Newswires
Lantern Pharma Says Longer LP-300 Treatment Helped Lung Cancer Patients in Phase 2 Study
Jun 2, 12:50 PM · MT Newswires
Lantern Pharma Inc. (LTRN) stock is trading at US$0.83, -8.79% from the previous close of US$0.91.
The market cap for Lantern Pharma Inc. (LTRN) stock is approximately US$29.91M.
The 52-week high for Lantern Pharma Inc. (LTRN) stock is US$4.69.
The 52-week low for Lantern Pharma Inc. (LTRN) stock is US$0.83.
Lantern Pharma Inc. (LTRN) does not currently pay a dividend.
Stay on top of LTRN
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
